

Calcium, Calcimimetics and Clinical Outcomes

Geoffrey Block

Denver Nephrology, Denver, Colorado

Clin J Am Soc Nephrol 1: 170–171, 2006. doi: 10.2215/CJN.00200106

The introduction of less-calcemic vitamin D analogs in 1998 was the beginning of a fundamental change in the management paradigm for secondary hyperparathyroidism in patients with chronic kidney disease (1). Until that time, the prevailing treatment strategy involved maintaining serum calcium (Ca) at the upper limit of normal to facilitate calcium-induced suppression of parathyroid hormone (PTH) synthesis and secretion. The inevitable transient episodes of hypercalcemia were viewed as a clinical management “nuisance” requiring temporary interruption of vitamin D therapy. Concurrent with the availability of this new therapeutic agent, which suggested the promise of having fewer episodes of hypercalcemia, observational evidence emerged, which suggested that patients with a lower calcium \times phosphorus (P) product (Ca \times P), lower serum Ca, and lower serum P had a survival advantage as compared with those with higher serum levels of these ions (2,3).

There have been a number of distinct data sets examining the relationship between serum Ca and clinical outcomes. Data from a large dialysis chain in the United States reveal that for each 1 mg/dl increase in Ca there is an observed 18 to 25% increase in the risk of death ($P < 0.0001$) (4). Multivariable adjusted data from the international Dialysis Outcomes and Practice Patterns (DOPPS) study suggest a 12% increase in all-cause mortality ($P < 0.0001$) and a 13% increase in cardiovascular specific mortality ($P < 0.0001$) per 1 mg/dl increase in albumin-adjusted serum Ca (5). However, data from the Canadian Patient Registration, Management and Outcome Information System (PROMIS) database and from the Netherlands COoperative Study into the Adequacy of Dialysis treatment (NECOSAD) database do not find an independent relationship between serum Ca and mortality (although both report a relationship with Ca \times P) (3,6).

Though important, these observations had limited practical applicability until the introduction of calcimimetic agents in 2004. This new class of therapeutic agents acts as allosteric modulators of the Ca-sensing receptor and allow for suppression of PTH synthesis and secretion while simultaneously lowering serum Ca and P (7).

As shown by Srinivas *et al.*, calcimimetic agents can effectively suppress serum Ca in patients who have persistent sec-

ondary hyperparathyroidism and hypercalcemia after kidney transplant (8). Using low-dose cinacalcet, the investigators were able to effectively treat hypercalcemia while modestly suppressing PTH. Importantly, the serum P rose significantly, an effect predicted by the effects of PTH on P resorption. These results are similar to other small case series reported in the posttransplant population.

Chertow *et al.* studied the simultaneous reduction of active vitamin D to “physiologic levels” and the introduction of cinacalcet to subjects with controlled PTH and elevated Ca \times P (9). These investigators report a significant improvement in the proportion of subjects achieving Kidney Disease Outcomes Quality Initiative (K/DOQI) PTH and Ca \times P targets despite the discontinuation of active vitamin D in 21% of subjects and a reduction of active vitamin D dose by nearly 50% in the remainder. The proportion of subjects given Ca-containing phosphate binders increased from 62% to 79% and the mean dose of elemental Ca prescribed rose to 1847 mg/d.

These clinical trials provide ongoing evidence that the introduction of calcimimetic drugs represents a real opportunity to improve the paradigm of managing the biochemical variables associated with secondary hyperparathyroidism. However, neither of these clinical trials demonstrates a tangible effect of Ca reduction on clinical outcomes. While the effective treatment of hypercalcemia and secondary hyperparathyroidism is of considerable clinical interest, it remains to be seen whether this will translate into improvement in bone health or cardiovascular outcomes. The increase in serum P seen in patients with chronic kidney disease stages 2 to 4 and the increase in Ca burden associated with cinacalcet use in stage 5 warrant further investigation as they may significantly modify the independent effect of cinacalcet.

Despite the robust body of observational data supporting the hypothesis that lower serum Ca is associated with improved clinical outcomes, there have been no randomized clinical trials to test this hypothesis. The same can be said for serum P and Ca \times P. It is reassuring that Cunningham *et al.* (10) report significantly improved meaningful clinical outcomes such as fracture and hospitalizations and a trend toward improved mortality in patients studied during the clinical development of cinacalcet; however, the question remains: Will interventions that specifically lower serum Ca, serum P, and PTH improve cardiovascular outcomes and alter all-cause survival in patients with end-stage renal disease? (10)

A very large, international, prospective, randomized, clinical trial to test this hypothesis is currently being developed. I

Published online ahead of print. Publication date available at www.cjasn.org.

Address correspondence to: Dr. Geoffrey Block, Denver Nephrology, 130 Rampart Way, Suite 175, Denver, CO 80230. Phone: 303-364-4775; Fax: 303-830-6025; E-mail: gablock@denverneph.net

believe this to be a critical step to establish a causal role for abnormalities of mineral metabolism in the burden of cardiovascular disease in subjects with chronic kidney disease. Until the time that such a study is completed, the current weight of evidence supports that serum Ca and serum P should be maintained in the low normal range and that the introduction of cinacalcet offers a unique opportunity to do so.

References

1. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-alpha-25-Dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone patients on hemodialysis. *J Am Soc Nephrol* 9: 1427–1432, 1998
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium \times phosphate product with mortality risk in chronic hemodialysis patients: A national study. *Am J Kidney Dis* 31: 607–617, 1998
3. Stevens LA, Djurdejev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. *J Am Soc Nephrol* 15: 770–779, 2004
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 15: 2208–2218, 2004
5. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 44[Suppl 3]: S34–S38, 2004
6. Noordzij M, Korevaar J, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group: The Kidney Disease Outcomes Initiative (K/DOQI) Guidelines for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients. *Am J Kidney Dis* 46: 925–932, 2005
7. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suryani MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Druke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 350: 1516–1525, 2004
8. Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, Meier-Kriesche H-U: Improvement in hypercalcemia with cinacalcet after kidney transplantation. *Clin J Am Soc Nephrol* 1: 323–326, 2005
9. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J; on behalf of the CONTROL Investigator: Cinacalcet hydrochloride (sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium \times phosphate. *Clin J Am Soc Nephrol* 1: 305–312, 2005
10. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. *Kidney Int* 68: 1793–1800, 2005

Please see the related articles, “Improvement in Hypercalcemia with Cinacalcet after Kidney Transplantation,” on pages 323–326 and “Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium \times Phosphate,” on pages 305–312.

Clinical use of the calcimimetic cinacalcet in hemodialysis (Chertow *et al.*) and transplant patients (Srinivas *et al.*) with the corresponding editorial by Block are featured in this month’s *CJASN*. A study in experimental animals on another congener by Lopez *et al.* in this month’s *JASN* (pages 795–804) shows a decrease in extraosseous calcifications, even in calcitriol-treated animals.